Bristol-Myers says panel finds Opdivo lung cancer study meets endpoint

January 12, 2015 3:40 AM

17 0

(Reuters) - Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint.

The company said the data demonstrates superior overall survival in patients receiving Opdivo compared to the control arm, indicating a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer.

Read more

To category page